Literature DB >> 6837602

Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count.

N Kemeny, D W Braun.   

Abstract

In 220 patients with advanced colorectal carcinoma, objective tumor response to chemotherapy and survival were related to the following parameters: age, sex, performance status, time interval from diagnosis to metastases, initial site of metastases, and initial white blood cell count, lactic dehydrogenase, alkaline phosphatase, and carcinoembryonic antigen levels. Each variable was first evaluated separately. By conventional statistical methods, none of the variables significantly predicted response, although the following parameters significantly (p less than 0.01) predicted survival: Patients with an initially normal level of lactic dehydrogenase versus those with an abnormal level of lactic dehydrogenase had median survivals of 16 and 7.0 months, respectively; normal versus abnormal carcinoembryonic antigen levels, 23 and 9.2 months, respectively; white blood cell count of less than 10,000 versus greater than 10,000 cells/mm3, 11 and 7.0 months, respectively; performance status of greater than 70 versus less than 60, 11 and 6.6 months, respectively; and lung versus liver metastases, 12 and 8.0 months, respectively. By studying the variables together with multivariate analysis, we found that the most important variables in predicting response were the lactic dehydrogenase level and the white blood cell count. In predicting survival, the most important variables were the lactic dehydrogenase level, performance status, and lung involvement. We recommend that future randomized therapeutic trials for advanced colorectal carcinoma should delineate and perhaps stratify for the lactic dehydrogenase level, performance status, white blood cell count, and/or the presence of lung involvement.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6837602     DOI: 10.1016/0002-9343(83)91066-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  25 in total

1.  KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.

Authors:  Nancy E Kemeny; Joanne F Chou; Marinela Capanu; Alexandra N Gewirtz; Andrea Cercek; T Peter Kingham; William R Jarnagin; Yuman C Fong; Ronald P DeMatteo; Peter J Allen; Jinru Shia; Celina Ang; Efsevia Vakiani; Michael I D'Angelica
Journal:  Cancer       Date:  2014-08-25       Impact factor: 6.860

2.  Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: a meta-analysis.

Authors:  Jian Chen; Meng-xiong Sun; Ying-qi Hua; Zheng-dong Cai
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-31       Impact factor: 4.553

3.  Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases.

Authors:  Louise C Connell; Taryn M Boucher; Joanne F Chou; Marinela Capanu; Stephanie Maldonado; Nancy E Kemeny
Journal:  J Surg Oncol       Date:  2016-12-23       Impact factor: 3.454

4.  Baseline hemoglobin and liver function predict tolerability and overall survival of patients receiving radioembolization for chemotherapy-refractory metastatic colorectal cancer.

Authors:  Andrew S Kennedy; David Ball; Steven J Cohen; Michael Cohn; Douglas M Coldwell; Alain Drooz; Edward Ehrenwald; Samir Kanani; Fred M Moeslein; Charles W Nutting; Samuel G Putnam; Steven C Rose; Michael Savin; Sabine Schirm; Navesh K Sharma; Eric Wang
Journal:  J Gastrointest Oncol       Date:  2017-02

Review 5.  Prognostic and predictive response factors in colorectal cancer patients: between hope and reality.

Authors:  Chiara De Divitiis; Guglielmo Nasti; Massimo Montano; Rossella Fisichella; Rosario Vincenzo Iaffaioli; Massimiliano Berretta
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

6.  Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.

Authors:  Benoist Chibaudel; Franck Bonnetain; Christophe Tournigand; Leila Bengrine-Lefevre; Luis Teixeira; Pascal Artru; Jérôme Desramé; Annette K Larsen; Thierry André; Christophe Louvet; Aimery de Gramont
Journal:  Oncologist       Date:  2011-08-22

7.  Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma.

Authors:  Enrique González-Billalabeitia; Ricardo Hitt; Jesús Fernández; Esther Conde; Francisco Martínez-Tello; Rafael Enríquez de Salamanca; Hernán Cortés-Funes
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405

Review 8.  Genetic prognostic and predictive markers in colorectal cancer.

Authors:  Axel Walther; Elaine Johnstone; Charles Swanton; Rachel Midgley; Ian Tomlinson; David Kerr
Journal:  Nat Rev Cancer       Date:  2009-06-18       Impact factor: 60.716

9.  Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer.

Authors:  T G Allen-Mersh; N Kemeny; D Niedzwiecki; B Shurgot; J M Daly
Journal:  Gut       Date:  1987-12       Impact factor: 23.059

10.  Predicting tumor response in patients with colorectal hepatic metastases.

Authors:  J M Daly; J Butler; N Kemeny; S D Yeh; J A Ridge; J Botet; J R Bading; J J DeCosse; R S Benua
Journal:  Ann Surg       Date:  1985-09       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.